CD274 and non-small cell lung carcinoma: In the expansion cohort of pretreated advanced NSCLC (NCT02517398), bintrafusp alfa treatment showed an encouraging efficacy with an ORR of 21.3% (17/80) in all patients and 85.7% (6/7) in patients with PD-L1-high (11).